Aeterna Zentaris Newly Appointed CEO, David A. Dodd, to Host Introductory Analyst and Investor Conference Call on Thursday, April 25, 2013

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\n\n\n\nQUEBEC CITY, April 23, 2013 /CNW Telbec/ - Aeterna Zentaris Inc.\n (NASDAQ: AEZS) (TSX: AEZ) (the \"Company\") newly appointed President and\n CEO, David A. Dodd will hold an introductory analyst and investor\n conference call on Thursday, April 25, 2013 at 4:30 p.m., Eastern Time.\n\n\nParticipants may access the live webcast via the Company's website at www.aezsinc.com in the \"Newsroom\" section, or by telephone using the following numbers:\n in Canada, 514-807-9895 or 647-427-7450, outside Canada, 888-231-8191.\n A replay of the webcast will also be available on the Company's website\n for a period of 30 days.\n\n\nAbout Aeterna Zentaris \n\n\nAeterna Zentaris is an oncology and endocrinology drug development\n company currently investigating treatments for various unmet medical\n needs. The Company's pipeline encompasses compounds at all stages of\n development, from drug discovery through to marketed products. For more\n information please visit www.aezsinc.com.\n\nSOURCE: AETERNA ZENTARIS INC.\n\n\n Investor Relations Ginette Beaudet Vallières Investor Relations Coordinator (418) 652-8525 ext. [email protected] Media Relations Paul Burroughs Director of Communications (418) 652-8525 ext. [email protected] \n","length":1689,"tagName":"div"}]

More updates from Cosciens Biopharma Inc.